Novartis 28 avr. 2026 Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies - Fierce Pharma
Novartis 28 avr. 2026 Novartis’ sales dip as generics pressure intensifies, radioequivalents loom - BioSpace
Novartis 28 avr. 2026 Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months' - CNBC
Novartis 28 avr. 2026 Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works - Fierce Biotech
Novartis 27 avr. 2026 Biopharma bites: 'Green shoots' for UK's biotech sector, Ligand buys XOMA and more from AstraZeneca, Novartis - FirstWord Pharma
FierceBiotech 22 avr. 2026 Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
Novartis 20 avr. 2026 Novartis Restructures Clinical Ops to Scale Trial Innovation Beyond Pilots - The Clinical Trial Vanguard
FierceBiotech 15 avr. 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
Endpoints News 23 mars 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
FierceBiotech 23 mars 2026 Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
FierceBiotech 20 mars 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Endpoints News 20 mars 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 26 févr. 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer